Skip to main content
Journal of Clinical and Diagnostic Research : JCDR logoLink to Journal of Clinical and Diagnostic Research : JCDR
. 2015 Oct 1;9(10):LC13–LC17. doi: 10.7860/JCDR/2015/14986.6694

Hepatitis C Seroprevalence and Risk Factors in Adult Population of Chaharmahal and Bakhtiari Province of Iran in 2013

Masoumeh Moezzi 1,, Reza Imani 2, Ali Karimi 3, Behrouz Pourheidar 4
PMCID: PMC4625265  PMID: 26557546

Abstract

Introduction

Hepatitis C is the second leading viral infectious disease worldwide. In Iran, hepatitis C is the most important and prevalent reason for chronic hepatitis and liver cirrhosis in the multi transfused population.

Aim

This study was conducted to determine seroprevalence and burden of hepatitis C in Chaharmahal and Bakhtiari province and to plan for controlling it.

Materials and Methods

For this analytical, population-based study, 3000 samples older than 15 years old were enrolled from urban and rural areas of Chaharmahal and Bakhtiari province, southwest Iran per cluster sampling. Written informed consent was obtained from the participants and the demographic data, transmission route and risk factors were collected after blood sample taking. Hepatitis C virus antibody (HCV Ab) and western blotting were consecutively run.

Statistical Analysis

Data analysis was done by SPSS 19 using descriptive statistics, and chi-square test, Fisher’s exact test, and logistic regression Ap value of 0.05 was considered as the level of significance.

Results

The prevalence of HCV Ab was obtained 1.4% (95% CI, 0.95-1.7) and that of positive hepatitis C by western blotting 0.9% (95% CI, 0.65-1.3). The prevalence in men (1.2%) was obtained two times higher than women. The highest prevalence was obtained in 35 to 44-year-old population (2%). The prevalence was higher in married individuals and less in higher educated. History of hospital stay, first degree relatives infected with HCV, jaundice, history of blood transfusion, tattoo, outpatient surgery, imprisonment, contact with the infected, intravenous (IV) drug abuse, and smoking had significant association with disease prevalence (p<0.05). The highest odds ratio was obtained for history of IV drug abuse (OR=38.2, 95% CI, 14.06-103.9) followed by imprisonment (OR=8.9, 95% CI, 2.97-26.6). However, by logistic regression only history of IV drug abuse was obtained as significant (p<0.05).

Conclusion

Hepatitis C is growing and emerging as the most prevalent chronic, viral hepatic disease, so further consideration of risk factors and routes of transmission is crucial for appropriate planning for, and preventing, treating, and controlling hepatitis C. IV drug abusers as the most important group need special consideration and surveillance in order to cut infection chain and decrease the disease incidence.

Keywords: Antibodies, Seroepidemiologic studies, Viral infectious disease

Introduction

Hepatitis C, after hepatitis B, is the second leading viral infectious disease worldwide and its significance relates to the development of hepatic diseases and the associated complications [1]. The prevalence of hepatitis C is about 3% globally and the number of infected individuals is estimated about 130-170 million [14]. This virus is the most prevalent reason for chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma in North America, Europe, and Japan and the most important reason for liver transplantation in the United States [5,6].

In Iran, hepatitis C is the most important and prevalent reason for chronic hepatitis and liver cirrhosis in the multi transfused population (thalassemia, hemophilia, and hemodialysis). Prevalence of hepatitis C is much less than hepatitis B in Iran, so that 0.3% of volunteer blood donors (compared with 4% in Egypt, 2.2% in Japan, and 1.4% in Africa) and less than 10% of the patients with chronic hepatitis or liver cirrhosis in their serum in Tehran, were eligible for anti-hepatitis C virus antibodies (HCV Abs) [5]. In most developed countries prevalence is under 1%, but in Asian countries the prevalence is higher. For example, the prevalence of hepatitis C was reported 0.3% in Germany [7], 0.06% in North America [8], 2.4% in Lithuania [9], 1.2% in Brazil and Libya [10,11], 5.2% in India [12], and 4.8% in Pakistan [13]. In Iran, most studies have been conducted on high risk populations; the prevalence of hepatitis C was reported 11-25% in hemodialysis patients, 11-52% in intravenous (IV) drug abusers, and 15-76% in hemophilia and thalassemia patients [5,1417].

The study of blood donors in Iran from 2004 to 2007 reported the prevalence 0.13% [18] and the prevalence in blood donors in Shahrekord, capital of Chaharmahal and Bakhtiari was reported 0.6% [19]. However, the prevalence estimated for Iran general population was less than 1%, which is less than the countries of the region [5]. Some recent, population-based studies confirm this finding. The findings of these studies represent the difference in population prevalence among different provinces and regions of Iran, which could be attributed to the contribution of lifestyle, and cultural and ethnicity-related conditions to hepatitis C prevalence and the associated risk factors [2022]. Regarding these differences and the limited number of population-based studies on prevalence of hepatitis C, and the necessity of conducting such investigation in Chaharmahal and Bakhtiari to study the prevalence and risk factors of this disease in the community, this population-based study was conducted, following the recommendation of the University Committee of Hepatitis, to determine the burden of disease and to plan for controlling the infection and disease.

Materials and Methods

In this analytical, population-based study, adults over 15 years old in urban and rural areas of Chaharmahal and Bakhtiari comprise the sample population. With confidence interval 95%, relative error 25%, and 800000-individual population of the area under study, 3000 individuals were enrolled. The method of sampling was clustered, consisting of 50 60-individual clusters (32 urban, 18 rural). The inclusion criteria were 15 years and older, and consent to participate. The written consent to enter into the study was obtained from the participants to fill out the questionnaire, to take blood sample, and generally to observe research ethics. This study has ethics code of 90-2-6/1 of Ethics Committee of the University. Notably, the sample considered in the present study is similar to another study simultaneously approved with similar protocol and ethics code [23].

Three separate teams were formed for interview, blood sample taking, and laboratory to implement the study. Firstly, interview team referred houses, explained the purpose of the research project, and questioned the presence of qualified individual(s) in the house. If the answer was yes and the individual was consent to participate, the researchers asked him/her to fill out the questionnaire. For seroprevalence of hepatitis, two consecutive tests, HCV Ab and western blotting were used. By this way, to confirm the test, positive HCV Ab samples were further investigated by western blotting and the confirmed samples by western blotting were considered as hepatitis C-positive. HCV-Elisa was run with Dia-Pro kit (Italy) and western blotting with MP kit.

Statistical Analysis

Having entered the data into SPSS19 software, we did data analysis using descriptive parameters, and chi-square and Fisher’s exact test, and then significant factors in univariate analysis were entered into logistic regression model to eliminate probable confounding factors. The level of significance was considered 0.05.

Results

Mean age of the participants was 38.4±16.3 (range: 15-90) years old. 63% were female and 75% married. Initially, 40 of 3000 were HCVAb-positive and after running western blotting, HCVAb-positive cases declined to 27. Therefore, the prevalence of HCVAb was obtained 1.4% (95% CI, 0.95-1.7) and positive hepatitis C prevalence by western blotting was 0.9% (95% CI, 0.65-1.3).

The highest prevalence was obtained in Kiar and Ardal Counties (respectively 2.08% and 1.66%) and no positive western blotting was derived in Lordegan and Farsan [Table/Fig-1]. The prevalence in men was obtained 1.2%, two times higher than the prevalence in women. The highest prevalence (2.12%) was obtained in 35-44 years old population followed by 25-34 years old (0.9%) and 45-54 years old (0.8%) populations. The prevalence in married individuals was obtained 1.22%, two times higher than the prevalence in single individuals. The prevalence in Fars ethnicity (1%), civil servants (1.9%), non public occupations (1.58%), and the jobless (1.07%) was higher than others. The prevalence in cities (0.8%) and villages (0.7%) was approximately similar. For education, the highest prevalence was obtained in those able to read and the illiterate (1%) and as the education grew higher, the prevalence decreased [Table/Fig-1].

[Table/Fig-1]:

Prevalence of hepatitis C for demographic characteristics a At 0.05 level, p is significant

Total
Number
Positive
Cases
No.
(Western
blotting)
Prevalence
(%)
p-value
a Chi-Square
County 0.08
(Fisher’s
Exact
Test)
 Shahrekord 1680 15 0.89
 Boroujen 420 5 1.19
 Farsan 120 0 0
 Lordegan 300 0 0
 Ardal 60 1 1.66
 Kouhrang 180 1 0.55
 Kiar 240 5 2.08
 total 3000
Missing* 0
Gender 0.08
 Male 1111 14 1.26
 Female 1889 13 0.68
 total 3000
 missing 0
Age, years 0.01
 15-24 708 3 0.42
 25-34 766 7 0.91
 35-44 518 11 2.12
 45-54 456 4 0.87
 55-64 384 3 0.78
 >64 161 0 0
 Total 2993
 Missing 7
Marital status 0.3
 Single 717 4 0.55
 Married 2125 23 1.08
 Divorced/Widow 136 0 0
 Total 2978
 Missing 22
Ethnicity 0.04
 Fars 1549 19 1.22
 Turk 482 0 0
 Lor 904 8 0.88
 Total 2935
 Missing* 65
Residence 1
 Urban 1847 15 0.81
 Rural 1068 8 0.74
 Nomadic 5 0 0
 Total 2920
 Missing 80
Occupation 0. 1
(Fisher’s
Exact
Test)
 Civil Servant 151 3 1.98
 Non-Public 506 8 1.58
 Student 340 0 0
 Soldier 12 0 0
 Housewife 1495 12 0.80
 Retired 102 1 0.98
 Jobless 278 3 1.07
 Farmer and
poulterer
92 0 0
 Total 2976
 Missing* 24
Education 0.1
 Illiterate 629 6 0.95
 Able to read 1069 12 1.12
 Diploma and
above
1010 6 0.59
 MA/MSc and
above
268 1 0.37
 Total 2976
 Missing* 24

* Some items in questionnaire were not completed by all the participants

Chi-square indicated that out of the risk factors and the factors contributing to the transmission, history of hospital stay and jaundice, first degree relatives infected with HCV, and history of blood transfusion, tattoo, outpatient surgery, contact with hepatitis-infected individuals, imprisonment, intravenous (IV) drug abuse, and smoking were significantly associated with the disease prevalence. The highest odds ratio was obtained for history of IV drug abusers (OR=38.2, 95% CI, 14.06-103.9) followed by imprisonment (OR=8.9, 95%CI, 2.97-26.6) [Table/Fig-2]. However, by logistic regression (enter model), out of the above factors, only history of IV drug abuse was obtained as significant (p< 0.05).

[Table/Fig-2]:

Prevalence of hepatitis C for risk factors

Risk factor Total Number Positive Cases Number Prevalence% OR a CI p-value b Chi-Square
Hospitalization History 0.02
Yes 1595 19 1.19 6.7 1.06-4.3
No 1344 6 0.44
Total 2939
Missing* 61
Jaundice History 0.04
Yes 43 2 4.65 6.3 1.43-27.7
No 2868 22 0.76
Total 2911
Missing* 89
First degree relative, infected with virus 0.04
Yes 93 3 3.22 4.1 1.2-13.9
No 2871 23 0.80
Total 2964
Missing* 36
Transfusion history 0.03
Yes 72 3 4.16 5.42 1.59-18.5
No 2894 23 0.79
Total 2966
Missing* 34
Tattoo 0.002
Yes 307 9 2.9 4.68 2.06-10.5
No 2651 17 0.64
Total 2958
Missing* 42
Outpatient surgery history 0.002
Yes 514 11 2.1 3.55 1.62-7.7
No 2450 15 0.61
Total 2964
Missing* 36
Contact with the Infected 0.01
Yes 120 4 3.3 4.6 1.55-13.7
No 2824 21 0.74
Total 2944
Missing* 56
Imprisonment 0.002
Yes 63 4 6.3 8.9 2.97-26.6
No 2912 22 0.75
Total 2975
Missing* 25
IV Drug Abuse 0.005
Yes 29 6 20.68 38.2 14.06-103.9
No 2952 20 0.67
Total 2981
Missing* 19
Smoking 6.26 2.8-13.6 0.03
Yes 417 13 3.1
No 2545 13 0. 51
Total 2962
Missing* 38

a Abbreviations: OR, odds ratio; CI, confidence interval.

b At 0.05 level, p is significant.

* Some items in questionnaire were not completed by all the participants

Discussion

In this study, the prevalence of HCV Ab was obtained 1.4% and that of positive hepatitis C by western blotting was obtained 0.9% in Chaharmahal and Bakhtiari. The prevalence of hepatitis C has been already studied in high risk populations, but few studies have been conducted as population-based. A population-based study investigated prevalence of hepatitis C in three provinces in northern, central, and southern Iran; the general prevalence was reported 0.5%, and the prevalence in Golestan 1%, in Tehran 0.3%, and in Hormozgan 1.6% [20]. In a population-based study in Amol (Mazandaran province), the prevalence of hepatitis C was obtained 0.05% [21], and in another study in Zahedan 0.5% [22].

By the findings of a study, the prevalence of hepatitis C, similar to hepatitis B, was heterogenous and varied depending on cultural, ethnicity-related conditions and lifestyle among provinces [24]. Although the population-based prevalence of hepatitis B in Chaharmahal and Bakhtiari has been already obtained 1.3% [24], which is lower than national prevalence, but hepatitis C prevalence was higher than the general, national prevalence obtained in Merat et al., study [20]. Therefore, it seems that hepatitis C is being replaced as and turned into the most prevalent chronic, viral hepatic disease, which highlights greater emphasis on and necessity of appropriate planning for preventing, treating, and controlling it. This has been already confirmed by some studies in Iran and other countries [8,20].

In the present study, the prevalence was twice higher in men than women, which is consistent with most studies in Iran and other countries, and possibly attributable to more risk factors in men. The highest prevalence was obtained in 35-44 years old population followed by 25-34 years old and 45-54 years old populations. In similar studies, the prevalence was higher in older populations, as well [812]. The prevalence was obtained higher in married individuals than single, and lower in Turk and Lor populations than Fars. This could be due to different lifestyle and less frequent high risk behaviors. Study of the association between ethnicity and hepatocellular carcinoma could be helpful in this regard.

The occupations most involved were non-public, civil servants, and jobless. The prevalence was not much different between cities and villages. In a study in Pakistan, the prevalence was obtained higher in 20-49 years old population and was not different between men and women. The prevalence has been already reported higher in married individuals, the individuals with public and outside home occupations and low socioeconomic status [13], consistent with the present study. The prevalence was higher in the individuals with the education level lower than diploma. In other similar investigations, consistent with the present study, the prevalence was less in the individuals with higher education [813], which is due to enhanced knowledge, attitude, and practice in these individuals.

Out of the risk factors and the factors contributing to the transmission, hospital stay history, first degree relatives infected with HCV, and history of blood transfusion, tattoo, outpatient surgery, contact with hepatitis-infected individuals, imprisonment, IV drug abuse, and smoking were significantly associated with disease prevalence, which is consistent with other studies [520]. However, by logistic regression, only history of IV drug abuse was yielded as significant. Probably, imprisonment and smoking were not significant in the model due to association with IV drug abuse. In study of Iran’s three provinces, imprisonment and IV drug abuse were the main factors in the model [18]. In study of Amol, Mazandaran province, unsterile puncture and infection in first degree relatives were obtained as the main risk factors in the model [19], but in study of Zahedan, none of the risk factors were obtained as significant in multivariate analysis [20]. In this province, the highest odds ratio was obtained for IV drug abuse, so IV drug abuse seems to be the main factor. But, difference in ethnicity and probable effect of lifestyle should be considered, as well.

Conclusion

It seems that hepatitis C is growing as the most prevalent chronic, viral hepatic disease. Further consideration of risk factors and routes of infection transmission is crucial for appropriate planning for, and preventing, treating, and controlling hepatitis C. IV drug abusers as the most important group need special consideration and surveillance in order to cut infection chain and decrease the disease incidence.

Acknowledgments

This paper was derived from a research project (no. 985), funded by Deputy of Research and Technology of Shahrekord University of Medical Sciences and conducted with cooperation of Deputy of Health of this University.

Financial or Other Competing Interests

As Declared above.

References

  • [1].Craxi A, Laffi G, Zignego AL. Hepatitis C virus (HCV) infection: a systemic disease. Mol Aspects Med. 2008;29(1-2):85–95. doi: 10.1016/j.mam.2007.09.017. [DOI] [PubMed] [Google Scholar]
  • [2].Fallahian F, Najafi A. Epidemiology of hepatitis C in the Middle East. Saudi J Kidney Dis Transpl. 2011;22(1):1–9. [PubMed] [Google Scholar]
  • [3].Lavanchy D. The global burden of hepatitis C. Liver Int. 2009;29(Suppl 1):74–81. doi: 10.1111/j.1478-3231.2008.01934.x. [DOI] [PubMed] [Google Scholar]
  • [4].Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005;5(9):558–67. doi: 10.1016/S1473-3099(05)70216-4. [DOI] [PubMed] [Google Scholar]
  • [5].Azizi F, Janghorbani M, Hatami H. Epidemiplogy and control of common diseases in iran: Viral Hepatitis: Malekzade R. Riyahi A. 3rd ed. Tehran: Khosravi; 2012. [Google Scholar]
  • [6].Butt AA. Hepatitis C virus infection: the new global epidemic. Expert Rev Anti Infect Ther. 2005;3(2):241–49. doi: 10.1586/14787210.3.2.241. [DOI] [PubMed] [Google Scholar]
  • [7].Poethko-Muller C, Zimmermann R, Hamouda O, Faber M, Stark K, Ross RS, et al. [Epidemiology of hepatitis A, B, and C among adults in Germany: results of the German Health Interview and Examination Survey for Adults (DEGS1)] Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013;56(5-6):707–15. doi: 10.1007/s00103-013-1673-x. [DOI] [PubMed] [Google Scholar]
  • [8].Klevens RM, Miller J, Vonderwahl C, Speers S, Alelis K, Sweet K, et al. Population-based surveillance for hepatitis C virus, United States, 2006-2007. Emerg Infect Dis. 2009;15(9):1499–502. doi: 10.3201/eid1509.081050. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [9].Tolmane I, Rozentale B, Keiss J, Arsa F, Brigis G, Zvaigzne A. The prevalence of viral hepatitis C in Latvia: a population-based study. Medicina (Kaunas) 2011;47(10):532–35. [PubMed] [Google Scholar]
  • [10].Pereira LM, Martelli CM, Moreira RC, Merchan-Hamman E, Stein AT, Cardoso MR, et al. Prevalence and risk factors of Hepatitis C virus infection in Brazil, 2005 through 2009: a cross-sectional study. BMC Infect Dis. 2013;13:60. doi: 10.1186/1471-2334-13-60. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [11].Daw MA, El-Bouzedi A. Prevalence of hepatitis B and hepatitis C infection in Libya: results from a national population based survey. BMC Infect Dis. 2014;14:17. doi: 10.1186/1471-2334-14-17. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [12].Sood A, Sarin SK, Midha V, Hissar S, Sood N, Bansal P, et al. Prevalence of hepatitis C virus in a selected geographical area of northern India: a population based survey. Indian J Gastroenterol. 2012;31(5):232–36. doi: 10.1007/s12664-012-0251-8. [DOI] [PubMed] [Google Scholar]
  • [13].Qureshi H, Bile KM, Jooma R, Alam SE, Afridi HU. Prevalence of hepatitis B and C viral infections in Pakistan: findings of a national survey appealing for effective prevention and control measures. East Mediterr Health J. 2010;16(Suppl):S15–23. [PubMed] [Google Scholar]
  • [14].Rezvan H, Abolghassemi H, Kafiabad SA. Transfusion-transmitted infections among multitransfused patients in Iran: a review. Transfus Med. 2007;17(6):425–33. doi: 10.1111/j.1365-3148.2007.00794.x. [DOI] [PubMed] [Google Scholar]
  • [15].Sharifi-Mood B, Eshghi P, Sanei-Moghaddam E, Hashemi M. Hepatitis B and C virus infections in patients with hemophilia in Zahedan, southeast Iran. Saudi Med J. 2007;28(10):1516–19. [PubMed] [Google Scholar]
  • [16].Karimi M, Ghavanini AA. Seroprevalence of HBsAg, anti-HCV, and anti-HIV among haemophiliac patients in Shiraz. Iran. Haematologia (Budap) 2001;31(3):251–55. doi: 10.1163/15685590152763809. [DOI] [PubMed] [Google Scholar]
  • [17].Mirmomen S, Alavian SM, Hajarizadeh B, Kafaee J, Yektaparast B, Zahedi MJ, et al. Epidemiology of hepatitis B, hepatitis C, and human immunodeficiency virus infecions in patients with beta-thalassemia in Iran: a multicenter study. Arch Iran Med. 2006;9(4):319–23. [PubMed] [Google Scholar]
  • [18].Kafi-abad SA, Rezvan H, Abolghasemi H, Talebian A. Prevalence and trends of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus among blood donors in Iran, 2004 through 2007. Transfusion. 2009;49(10):2214–20. doi: 10.1111/j.1537-2995.2009.02245.x. [DOI] [PubMed] [Google Scholar]
  • [19].Tajbakhsh E, Yaghobi R, Vahedi AR. A serological survey on hepatitis C virus Antibody in blood donors with an ELISA method. Tehran Univ Med J. 2007;65(8):69–73. [Google Scholar]
  • [20].Merat S, Rezvan H, Nouraie M, Jafari E, Abolghasemi H, Radmard AR, et al. Seroprevalence of hepatitis C virus: the first population-based study from Iran. Int J Infect Dis. 2010;14(Suppl 3):e113–16. doi: 10.1016/j.ijid.2009.11.032. [DOI] [PubMed] [Google Scholar]
  • [21].Zamani F, Sohrabi M, Poustchi H, Keyvani H, Saeedian FS, Ajdarkosh H, et al. Prevalence and risk factors of hepatitis C virus infection in amol city, north of iran: a population-based study (2008-2011) Hepat Mon. 2013;13(12):e13313. doi: 10.5812/hepatmon.13313. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [22].Ansari-Moghaddam A, Ostovaneh MR, Sharifi Mood B, Sanei-Moghaddam E, Modabbernia A, Poustchi H. Seroprevalence of hepatitis B surface antigen and anti hepatitis C antibody in zahedan city, iran: a population-based study. Hepat Mon. 2012;12(9):e6618. doi: 10.5812/hepatmon.6618. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [23].Moezzi M, Imani R, Khosravi N, Pourheidar B, Ganji F, Karimi A. Hepatitis B seroprevalence and risk factors in adult population of chaharmahal and bakhtiari province in 2013. Hepat Mon. 2014;14(5):e17398. doi: 10.5812/hepatmon.17389. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [24].Alavian SM, Hajarizadeh B, Ahmadzad-Asl M, Kabir A, Bagheri-Lankarani K. Hepatitis B Virus infection in Iran: A systematic review. Hepat Mon. 2008;8(4):281–94. [Google Scholar]

Articles from Journal of Clinical and Diagnostic Research : JCDR are provided here courtesy of JCDR Research & Publications Private Limited

RESOURCES